Logo image of CTXR

CITIUS PHARMACEUTICALS INC (CTXR) Stock Fundamental Analysis

NASDAQ:CTXR - Nasdaq - US17322U3068 - Common Stock - Currency: USD

0.8746  -0.05 (-4.93%)

After market: 0.8503 -0.02 (-2.78%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CTXR. CTXR was compared to 195 industry peers in the Pharmaceuticals industry. While CTXR seems to be doing ok healthwise, there are quite some concerns on its profitability. CTXR is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTXR had negative earnings in the past year.
In the past year CTXR has reported a negative cash flow from operations.
In the past 5 years CTXR always reported negative net income.
CTXR had a negative operating cash flow in each of the past 5 years.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -35.48%, CTXR perfoms like the industry average, outperforming 47.18% of the companies in the same industry.
The Return On Equity of CTXR (-71.05%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -35.48%
ROE -71.05%
ROIC N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

CTXR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

CTXR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CTXR has been reduced compared to 5 years ago.
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

CTXR has an Altman-Z score of -3.94. This is a bad value and indicates that CTXR is not financially healthy and even has some risk of bankruptcy.
CTXR's Altman-Z score of -3.94 is in line compared to the rest of the industry. CTXR outperforms 41.54% of its industry peers.
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CTXR has a Current Ratio of 0.37. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a worse Current ratio (0.37) than 94.36% of its industry peers.
A Quick Ratio of 0.06 indicates that CTXR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.06, CTXR is doing worse than 96.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.06
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

CTXR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -290.48%.
EPS 1Y (TTM)-290.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CTXR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.48%
EPS Next 2Y57.32%
EPS Next 3Y41.71%
EPS Next 5Y24.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTXR. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.42, which indicates a rather cheap valuation of CTXR.
CTXR's Price/Forward Earnings ratio is rather cheap when compared to the industry. CTXR is cheaper than 100.00% of the companies in the same industry.
CTXR is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.42
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTXR's earnings are expected to grow with 41.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.32%
EPS Next 3Y41.71%

More info and screens

0

5. Dividend

5.1 Amount

CTXR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (6/13/2025, 8:00:01 PM)

After market: 0.8503 -0.02 (-2.78%)

0.8746

-0.05 (-4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners7.63%
Inst Owner Change-3.53%
Ins Owners5.74%
Ins Owner Change0%
Market Cap9.00M
Analysts82.22
Price Target5.78 (560.87%)
Short Float %6.16%
Short Ratio1.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1789.22%
Min EPS beat(2)-3457.42%
Max EPS beat(2)-121.01%
EPS beat(4)0
Avg EPS beat(4)-900.03%
Min EPS beat(4)-3457.42%
Max EPS beat(4)-4.05%
EPS beat(8)1
Avg EPS beat(8)-503.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)14.39%
EPS NQ rev (3m)14.39%
EPS NY rev (1m)63.19%
EPS NY rev (3m)63.59%
Revenue NQ rev (1m)9.44%
Revenue NQ rev (3m)9.44%
Revenue NY rev (1m)-25.39%
Revenue NY rev (3m)-60.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.42
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.66
EYN/A
EPS(NY)2.09
Fwd EY239.08%
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-2.29
OCFYN/A
SpS0
BVpS5.89
TBVpS-4.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.48%
ROE -71.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.06
Altman-Z -3.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-290.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.6%
EPS Next Y84.48%
EPS Next 2Y57.32%
EPS Next 3Y41.71%
EPS Next 5Y24.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.88%
OCF growth 3YN/A
OCF growth 5YN/A